Drug
ZL-1310
ZL-1310 is a pharmaceutical drug with 4 clinical trials. Currently 4 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
4(100%)
Phase Distribution
Ph phase_1
3
75%
Ph phase_3
1
25%
Phase Distribution
3
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
4
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 13 (75.0%)
Phase 31 (25.0%)
Trials by Status
recruiting4100%
Recent Activity
4 active trials
Showing 4 of 4
recruitingphase_1
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
NCT07531095
recruitingphase_3
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146
recruitingphase_1
A Study of ZL-1310 in Participants With Selected Solid Tumors
NCT06885281
recruitingphase_1
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
NCT06179069
Clinical Trials (4)
Showing 4 of 4 trials
NCT07531095Phase 1
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
NCT07218146Phase 3
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT06885281Phase 1
A Study of ZL-1310 in Participants With Selected Solid Tumors
NCT06179069Phase 1
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4